IDEAYA and Servier Reports Successful Uveal Melanoma Trial; SynOx Therapeutics Highlights Positive Phase 3 TANGENT Topline Data; Regeneron and Telix Ink Strategic Radiopharma Deal; GSK Shares Promising Clinical Data on B7-H4-Targeted ADC; Replimune’s RP1 Hits Regulatory Hurdle with FDA Complete Response Letter

IDEAYA Biosciences and Servier Advance Darovasertib Program with Positive Registrational Trial Results

IDEAYA Biosciences and Servier have announced positive topline findings from the Phase 2/3 OptimUM-02 registrational trial evaluating the combination of darovasertib and crizotinib. The study targeted patients with first-line HLA-A*02:01-negative metastatic uveal melanoma (MUM), a population with historically limited therapeutic options. Darovasertib, a potent, selective small-molecule inhibitor of protein kinase C (PKC), was administered in combination with crizotinib, a cMET inhibitor, to exploit synergistic pathways in tumor suppression.

The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) as determined by independent central review. The combination therapy showed a robust clinical benefit compared to the investigator’s choice of chemotherapy, with a favorable hazard ratio. Furthermore, the objective response rate (ORR) and disease control rate (DCR) were markedly higher in the combination arm. The safety profile remained consistent with previous Phase 1/2 data, characterized primarily by manageable gastrointestinal and skin-related adverse events.

This success represents a major milestone in ocular oncology, as the combination addresses a critical genetic subset of MUM patients. IDEAYA and Servier have initiated preparations for a global regulatory filing, aiming to establish this regimen as the first-line standard of care. The companies believe these results validate the precision medicine approach of targeting the PKC/cMET axis in aggressive melanomas.

SynOx Therapeutics Reports Positive Topline Data from Phase 3 TANGENT Trial

Synox Therapeutics has released detailed topline results from the Phase 3 TANGENT study investigating emactuzumab in patients with Tenosynovial Giant Cell Tumor (TGCT). Emactuzumab is a novel monoclonal antibody designed to target and inhibit the Colony Stimulating Factor 1 Receptor (CSF1R), which plays a pivotal role in the recruitment and proliferation of the macrophages that drive TGCT progression.

The study met its primary efficacy endpoint, showing a statistically significant and clinically meaningful objective response rate (ORR) compared to the placebo group. Beyond tumor volume reduction, emactuzumab achieved statistically significant improvements in key secondary endpoints, including the Patient-Reported Outcomes (PRO) for pain and physical function. Patients treated with emactuzumab reported a substantial decrease in joint stiffness and a notable increase in range of motion, reinforcing the drug’s potential to improve quality of life.

The safety and tolerability profile was favorable, with the majority of treatment-emergent adverse events being low-grade and reversible. Unlike earlier generations of CSF1R inhibitors, emactuzumab showed a distinct lack of severe hepatotoxicity in this trial. Given the positive TANGENT data, Synox Therapeutics is moving forward with a rolling submission for its New Drug Application (NDA). The company anticipates that emactuzumab will fill a significant void in the treatment landscape for patients with symptomatic, non-resectable TGCT.

Regeneron and Telix Enter Strategic Radiopharmaceutical Partnership

Regeneron Pharmaceuticals and Telix Pharmaceuticals have entered into a strategic collaboration to accelerate the development of targeted radiopharmaceutical therapies (RPTs). This partnership merges Regeneron’s industry-leading antibody discovery platform, VelociSuite®, with Telix’s expertise in molecularly targeted radiation (MTR) and isotope supply chains. The primary focus of the alliance is to develop “theranostic” candidates, agents that can both image and treat cancer with high precision.

Under the terms of the agreement, the companies will initially focus on several high-priority targets in solid tumors, including urological cancers. Regeneron will lead the discovery and optimization of fully human monoclonal antibodies, while Telix will be responsible for the radioconjugation using therapeutic alpha and beta emitters. By delivering ionizing radiation directly to the tumor microenvironment, the collaboration aims to enhance cytotoxic effects while sparing healthy tissue, addressing the limitations of traditional external beam radiation.

Regeneron has committed to an upfront payment and a significant equity investment in Telix, with additional milestone payments contingent upon clinical and regulatory success. This collaboration signals a major strategic shift for Regeneron into the radiopharma space, leveraging Telix’s established global distribution network for radioactive isotopes. The partnership aims to initiate Phase 1 clinical trials for its first joint candidates within the next eighteen months, potentially redefining the treatment paradigm for metastatic solid tumors.

GSK Reveals Encouraging Findings for B7-H4 ADC in Gynecological Cancers

GSK has presented positive clinical data for its investigational B7-H4-targeted antibody-drug conjugate (ADC), GSK’457, in patients with advanced gynecological malignancies. The results, highlighted at a major oncology congress, focused on patients with ovarian and endometrial cancers who had progressed after standard platinum-based chemotherapy and immunotherapy. B7-H4 is a transmembrane protein overexpressed in these cancers, where it acts as an immune checkpoint ligand.

The ADC demonstrated a high degree of clinical activity, achieving a confirmed objective response rate (ORR) and a durable median duration of response (mDOR). By utilizing a high-affinity antibody conjugated to a potent topoisomerase inhibitor payload, the treatment showed effectiveness even in tumors with heterogeneous B7-H4 expression. Secondary endpoints, including progression-free survival (PFS) and overall survival (OS), showed encouraging trends compared to historical benchmarks for late-line therapy.

The safety profile was manageable, with neutropenia and nausea being the most frequently reported adverse events, consistent with the topoisomerase inhibitor class. GSK highlighted that the data support the “targeted strike” capability of ADCs to overcome the immunosuppressive environment typical of gynecological tumors. Following these results, GSK plans to initiate a pivotal Phase 3 program to evaluate the ADC in earlier lines of therapy, further expanding its growing oncology portfolio.

Replimune Receives FDA Feedback on RP1 Biologics License Application for Advanced Melanoma

Replimune Group, Inc. has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1. RP1 is an investigational oncolytic immunotherapy derived from a proprietary strain of herpes simplex virus type 1 (HSV-1), engineered to express a potent fusogenic protein and GM-CSF. The BLA sought approval for RP1 in combination with nivolumab for patients with advanced cutaneous squamous cell carcinoma (CSCC).

In the CRL, the FDA indicated that it cannot approve the application in its current form. While the agency did not raise concerns regarding the safety profile or the fundamental mechanism of the oncolytic virus, it requested additional clinical data to further substantiate the treatment’s efficacy over existing therapies. The FDA’s feedback specifically pointed to the need for longer-term follow-up from the primary registrational cohort to confirm the durability of the responses observed in the IGNYTE trial.

Replimune expressed disappointment but emphasized that the CRL provides a clear roadmap for resubmission. The company intends to work closely with the FDA to provide the requested data from its ongoing clinical programs. Despite this regulatory delay, Replimune remains confident in the potential of RP1 to transform the treatment of skin cancers and is continuing its other late-stage trials in melanoma and non-melanoma skin cancers. A formal meeting with the FDA is being scheduled to align on the timeline for an amended BLA filing.